Doctors in North Carolina still have options for treating COVID-19 patients who are uninsured. A state inventory revealed that there is still access the monoclonal antibody bebtelovimabtil for uninsured patients who are not a good fit for other authorized COVID-19 treatments.
Bebtelovimab went on the commercial market in August, thanks to a plan implemented by the North Carolina Department of Health and Human Services.
North Carolina’s current inventory of bebtelovimab is expected to last through the end of the summer if used at its current rate.
Providers can find more information and learn how to request supply on the NCDHHS COVID-19 website.